Shares of Rubius Therapeutics Inc (NASDAQ:RUBY) have earned a consensus broker rating score of 1.13 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.
Brokerages have set a 12-month consensus price target of $33.75 for the company and are forecasting that the company will post ($0.36) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Rubius Therapeutics an industry rank of 86 out of 255 based on the ratings given to its competitors.
A number of equities analysts have commented on RUBY shares. JPMorgan Chase & Co. started coverage on shares of Rubius Therapeutics in a research note on Monday, August 13th. They set an “overweight” rating on the stock. Jefferies Financial Group started coverage on shares of Rubius Therapeutics in a research note on Monday, August 13th. They set a “buy” rating and a $40.00 target price on the stock. Morgan Stanley started coverage on shares of Rubius Therapeutics in a research note on Monday, August 13th. They set an “overweight” rating and a $37.00 target price on the stock. Finally, Leerink Swann started coverage on shares of Rubius Therapeutics in a research note on Monday, August 13th. They set an “outperform” rating on the stock.
Rubius Therapeutics (NASDAQ:RUBY) last posted its quarterly earnings results on Friday, August 31st. The company reported ($3.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($2.73). During the same period in the previous year, the firm earned ($1.25) EPS. As a group, equities research analysts anticipate that Rubius Therapeutics will post -1.7 earnings per share for the current fiscal year.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
See Also: The risks of owning bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.